Rob attained a Masters in Natural Sciences from Cambridge University and his doctorate in Pharmacology from Oxford University. Prior to joining Script IP Ltd, he worked in the intellectual property department of Novartis and in private practices in the UK.
Rob specialises in biotechnology and pharmaceuticals. He has a particular interest in immunology, diagnostics, antibody technology, stem cells, molecular biology, bioinformatics, medical devices, food technology, gene therapy, drug delivery and formulation.
Rob has almost 20 years of professional experience in the field of intellectual property. He has gained much respect in the profession for his proven ability in advocacy in opposition and appeal proceedings. He is noted for his clear business focussed advice to clients ranging from academic institutions to multinational corporations on all aspects of patent law.
Rob regularly presents to audiences worldwide on a variety of topics in patent law. He has a wealth of experience in organising seminars and webinars on European biotech patent practice, including in the fields of antibodies, stem cells and recent EPO case law.
CXC chemokines generate age-related increases in neutrophil-mediated brain inflammation and blood-brain barrier breakdown. Current Biology (1998) 8(16):923-6.
Chemokine targets in acute brain injury and disease. Progress in Brain Research (2001) 132:507-24.
Script IP is a thoroughly professional business, who I would have no hesitation in recommending (except to our competitors).
Matt Quartley, Managing Director, Valeport Ltd